Basis: Four-quarter operating EBITDA / current FMP quote-based enterprise value × 100. Source: stored company filings and market data; unavailable inputs remain N/A.
The EBITDA yield is N/A as of 2026-10-06T19:10:32.285Z.
Calculation as of: 2026-10-06T19:10:32.285Z.
Quote observation: 2026-10-06T19:10:16.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 465112d98a6c82939a581bc37d9e1b887570666ec45509b145499b9afd19c223
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EBITDA YIELD
N/A
Market Cap
$53.55M
EBITDA Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$53.93M
EBITDA Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | EBITDA YIELD | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Aldeyra The (ALDX) | $53.29M | N/A | N/A | N/A | N/A |
| NOMAD Power Solutions, Inc. (NMAD)vs › | $53.15M | N/A | N/A | N/A | N/A |
| Zhengye Biotechnology Holding Limited (ZYBT)vs › | $53.55M | N/A | N/A | N/A | N/A |
| ImageneBio Inc (IMA)vs › | $53.01M | N/A | N/A | N/A | N/A |
| Spectral AI, Inc. (MDAI)vs › | $53.62M | N/A | N/A | N/A | N/A |
| Rani Therapeutics Holdings, Inc. (RANI)vs › | $53.93M | N/A | N/A | N/A | N/A |
| Eloxx Pharmaceuticals, Inc. (ELOX)vs › | $51.72M | N/A | N/A | N/A | N/A |
| biote Corp. (BTMD)vs › | $51.61M | 11.00% | 20.03% | 16.76% | 21.84% |
| eXoZymes, Inc. (EXOZ)vs › | $51.51M | N/A | N/A | N/A | N/A |
| Tenax Therapeutics, Inc. (TENX)vs › | $51.19M | N/A | 981.94% | 527.24% | 527.24% |
EBITDA Yield = TTM EBITDA / Enterprise Value
EBITDA yield is the inverse of EV/EBITDA, expressing trailing pre-interest, pre-tax operating cash generation as a percentage of enterprise value. Comparable across leverage levels; higher is cheaper. Not meaningful for banks and insurers.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
